New Jersey Governor Phil Murphy signed off on a bill allowing cannabis businesses in the state to claim state tax deductions, working around 280E.
The governor of New Jersey (NJ), Phil Murphy (D), recently signed a bill into law which provided licensed cannabis businesses the ability to deduct certain expenses from their state tax returns. It was a partial antidote for the cannabis industry which has been prevented from benefitting from federal deductions under the Internal Revenue Service (IRS) code, 280E.
Most states follow federal law but New Jersey’s new piece of legislation states that a licensed cannabis business’s gross income (1), “shall be determined without regard to section 280E of the [federal] Internal Revenue Code.” These businesses will still be subjected to the IRS 280E, which prevents establishments who illegally sell Schedule I or II drugs from taking part in key tax deductions in their federal filings. In NJ, licensed cannabis industry businesses will be able to experience some state-level relief.
This exciting legislation signed by Governor Murphy stated that it “shall apply to taxable years beginning on or after January 1 following enactment,” (1).
“The continued implementation of 280E placed severe financial constraints on cannabis operators, big and small, by prohibiting them from deducting common business expenses from their taxes,” the New Jersey Cannabis Trade Association said (1). “Now, New Jersey’s licensed cannabis operators will be treated like any other legal enterprise operating in New Jersey, a sense of normalcy that our industry will cherish.”
Last year, a fiscal analysis was performed and showed that the new law would possibly have mixed economic impacts. The decoupling from the federal 280E policy is anticipated to “result in an indeterminate annual loss of revenue” (1) for NJ because cannabis businesses would be qualified for relief from taxes they currently pay.
The Office of Legislative Services (OLS) added that “providing access to these deductions and credits may also help generate more economic activity by cannabis businesses,” and so “the State and local governments that tax cannabis businesses might indirectly realize an indeterminate amount of additional annual revenue,” (1).
Reference
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
Assessing Cannabis as a Harm Reduction Strategy: Insights from a Large-Scale Study
November 19th 2024A New Zealand study aimed to assess cannabis use as a harm reduction tool. Findings highlight lifestyle factors, and suggest cannabis-focused harm reduction strategies in reducing other substance use such as alcohol.
Ep 23, Part III: Accreditation in the Cannabis Industry with Susan Audino
October 24th 2024In Part III of this episode, host Evan Friedmann is joined by Susan Audino, PhD, founder of S.A. Audino & Associates, LLC, and co-founder of Saturn Scientific, LLC, to examine the complexities of sampling in the cannabis industry, emphasizing the need for proper sampling plans, and methods.